| Trial ID # | NCT03531645 |
| Phase | II |
| Drug Class | Cell Cycle Inhibitors: CDK4/6 |
| Drug Name | Abemaciclib |
| Alternate Drug Names | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio |
| Drugs in Trial | Abemaciclib, Fulvestrant |
| Eligible Participant | Newly diagnosed stage III/IV unresectable low grade serous ovarian cancer |
| Patients Enrolled | 15 |
| Therapy Setting | First-line |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, evaluated per RECIST |
| Efficacy | ORR: 60% (1CR, 7PR) 7 patients w/ IDS: |
| Clinically Significant Adverse Events | Serious AE: none |
| Conclusion | Neoadjuvant treatment with fulvestrant and abemaciclib is tolerable and demonstrates unprecedented response and complete gross resection rates in Low Grade Serous ovarian cancer |
| Reference | Cobb LP et al. A pilot phase II study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma. J Clin Oncol 40, 2022 (suppl 16; abstr 5522) Cobb LP et al. Poster |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.